Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)-Reference-Cited by-同舟云学术

Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)

Published:2017 Issue: Volume:2 Page:e000112
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Yang Haihong,Deng Qiuhua,Qiu Yuan,Huang Jun,Guan Yubao,Wang Fengnan,Xu Xin,Yang Xinyun

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Role of stereotactic radiosurgery in the treatment of brain metastases;Hazard;Am J Clin Oncol,2005

2. Current management of brain metastases, with a focus on systemic options;Langer;J Clin Oncol,2005

3. Treatment of brain metastasis from lung cancer;Chi;Cancers,2010

4. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells;Giovannetti;Mol Pharmacol,2008

5. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells;Li;Clin Cancer Res,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT;Journal of Cancer Research and Clinical Oncology;2024-02-19

2. Clinical Characteristics and Prognostic Factors of Leptomeningeal Metastasis in Nonsmall Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations;2024

3. Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis;Frontiers in Oncology;2022-01-20

4. First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials;2020-04-17

5. How I treat cancer special issue;ESMO Open;2019